I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Cervical cancer is the fourth most common cancer in women and the fourth prominent cause of cancer-caused mortality in women worldwide, with nearly 275,000 deaths per year.\[[@ref1]\] Many biological factors have been demonstrated to affect the progression of cervical cancer.\[[@ref2][@ref3]\] Due to poor understanding of molecular mechanisms underlying the initiation and progression of cervical cancer, the prognosis of cervical cancer is still unsatisfied. At present, long noncoding RNAs (lncRNAs), with length \>200 nucleotides, have been identified as critical regulators in multiple biological processes, including tumorigenesis. For example, Huang *et al*.\[[@ref4]\] reported that lncRNA *LINC00673* could be activated by SP1 and exerted its oncogenic properties through interacting with LSD1 and EZH2 in gastric cancer; Jin *et al*.\[[@ref5]\] demonstrated that upregulation of lncRNA *PlncRNA-1* promotes proliferation and induces epithelial--mesenchymal transition in prostate cancer; moreover, Li *et al*.\[[@ref6]\] revealed that *LINC00672* contributed p53-mediated gene suppression and promoted endometrial cancer chemosensitivity. Recently, many lncRNAs are reported to be associated with the progression and development of cervical cancer, such as *TUG1, MALAT1, XIST*, and *ANRIL*.\[[@ref7][@ref8][@ref9][@ref10]\] However, the pathophysiological processes and the specific molecular mechanisms of cervical cancer still need to be further investigated. Nuclear-enriched abundant transcript 1 (*NEAT1*) is a 3.2 kb novel nuclear lncRNA which is transcribed from the multiple endocrine neoplasia locus.\[[@ref11]\] Dysregulation of *NEAT1* has shown to be involved with non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and pancreatic cancer.\[[@ref12][@ref13][@ref14][@ref15]\] Up to date, the biological function of *NEAT1* in cervical cancer has been rarely discussed. This study focused on the biological function and mechanism of *NEAT1* in cervical cancer progression.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study had been approved by the Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University. Informed consent forms were obtained from all patients before this study.

Tissue samples {#sec2-2}
--------------

A total of 62 pairs of human cervical cancer tissues and adjacent normal tissues were obtained from the Affiliated Suzhou Hospital of Nanjing Medical University between September 2012 and September 2017. Patients included in the study received no chemotherapy or radiotherapy before surgery. The loss rate is about 7%. The age of all patients ranged from 38 to 60 years. The median age was 50 years. The method for sample selection was random sampling. Samples were snap-frozen and stored in liquid nitrogen as soon as they were collected.

Cell culture and transfection {#sec2-3}
-----------------------------

Four cervical cancer cell lines (CaSki, HeLa, ME-180, and SiHa) and normal human cervical epithelial cell line (H8) were obtained from American Type Culture Collection and cultured in humidified air at 37°C with 5% CO~2~ in Dulbecco\'s modified Eagle\'s medium media (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), penicillin (100 U/ml), and streptomycin (100 U/ml). Cervical cancer cell lines were transfected with 50 nmol/L Small-interfering RNA (si-RNA) specifically targeted to *NEAT1* (si-*NEAT1*) and negative control siRNA (si-NC) using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Forty-eight-hour after transfection, total cells were harvested for total RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR) analysis.

RNA extraction and quantitative real-time polymerase chain reaction {#sec2-4}
-------------------------------------------------------------------

Total RNA was isolated by TRIzol Reagent (Invitrogen) following the manufacturer\'s instructions. After RNA extraction, RNA samples were reversely transcribed by the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The FastStart Universal SYBR Green Master (Roche, USA) was applied for the qRT-PCR. The following primers were used to detect the expression of *NEAT1* and GAPDH (internal control) -- *NEAT1* (sense): 5'-CTTCCTCCCTTT AACTTATCCATTC-AC-3' and *NEAT1* (antisense): 5'-CTCTTCCTCCACCATTACCAACAATAC-3'; GAPDH (sense): 5'-AGAAGGCTGGGGCTCATTTG-3' and GAPDH (antisense): 5'-AGGGGCCATCACAGTCT TC-3'. The relative fold changes of candidate genes were analyzed using 2^−ΔΔCT^ method.

Cell viability assay {#sec2-5}
--------------------

Cell proliferation of cervical cancer cells was measured using MTT kit (Sigma, San Francisco, CA, USA). Briefly, logarithmically growing cervical cancer cells were trypsinized from culture dishes and placed at a density of 2 × 10^3^ cells per well into a 96-well plate and transfected with indicated vector. Cell proliferation was assessed 12, 24, 48, 72, and 96 h after transfection. Spent medium was replaced with fresh medium containing MTT 0.5 mg/ml. After incubated at 37°C for another 2 h, the medium was removed and 100 μl of DMSO (Sigma) was added to each well and plates, agitating for 10 min. Absorbance was assessed at 490 nm by a spectrophotometer (BioTek, Winooski, Vermont, USA).

Colony formation assay {#sec2-6}
----------------------

Cells (500 cells/well) transfected with indicated vector were plated in 6-well plates and incubated at 37°C. Two weeks later, the cells were fixed and stained with 0.1% crystal violet. The number of visible colonies was counted manually.

Cell migration assay {#sec2-7}
--------------------

Cell migration was detected using Transwell chambers (8-mm pore size; Millipore, Billerica, MA, USA). In brief, 600 ml complete medium was added to the bottom chamber, transfected cells were suspended in serum-free medium, and 200 ml of the cell suspension (containing 1 × 10^5^ cells) was placed in the upper chamber. After 48 h, the cells on the top surface of the membrane were mechanically removed using a cotton swab, and the cells on the bottom surface of the membrane were fixed in 95% ethanol and stained with 0.2% crystal violet solution. Cells adhering to the bottom surface of the membrane were counted in five randomly selected areas under microscope field. Each experiment was repeated three times.

Western blotting analysis {#sec2-8}
-------------------------

Cell proteins were prepared using cell lysis buffer. Equal amounts of protein (50 mg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (Millipore) by electroblotting. The membranes were blocked with 5% nonfat dry milk in TBST for 1 h and then incubated with primary antibody (anti-phosphorylated PI3K \[p-PI3K\], total PI3K, anti-phosphorylated Akt \[p-Akt\], total Akt, and anti-GAPDH; Abcam, Cambridge, UK) overnight at 4°C before subsequent incubation with second antibody (Cell Signaling Technology, MA, USA) for 1 h at 37°C. Protein bands were visualized using enhanced chemiluminescence reagent (Pierce, Thermo Fisher Scientific, Inc.).

Statistical analysis {#sec2-9}
--------------------

The statistical analysis was performed with SPSS software version 19.0 (IBM Corp., Armonk, NY, USA). The data were analyzed and presented as mean ± standard deviation (SD). Continuous variables were compared using the Student\'s *t*-test or the analysis of variance (ANOVA) test. Pearson χ^2^ test was used to evaluate the relationship between *NEAT1* expression and clinical features. Survival analysis was performed using the Kaplan-Meier method, and the log-rank test was used to compare the differences between patient groups. A *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Upregulated nuclear-enriched abundant transcript 1 expression in human cervical cancer tissues and cell lines {#sec2-10}
-------------------------------------------------------------------------------------------------------------

To explore whether *NEAT1* was abnormal expressed in the cervical cancer tissues, qRT-PCR was performed to measure the level of *NEAT1* in 62 cervical cancer tissues and corresponding normal tissues. As illustrated in [Figure 1a](#F1){ref-type="fig"}, the expression level of *NEAT1* in cervical cancer tissues was 5.155 ± 2.089 which was higher than that in normal tissues which the expression level was 1.396 ± 1.079 (*t* = 11.15, *P* = 0.007). Subsequently, the level of *NEAT1* was tested in four cervical cancer cell lines (HeLa, ME-180, SiHa, and CaSki) and one normal human cervical epithelial cell line (H8) \[[Figure 1b](#F1){ref-type="fig"}\]. The expression of *NEAT1* in H8 cell was set as 1, the relative higher level of *NEAT1* was detected in CC cells. The expression quantity of *NEAT1* in CC cells was shown as follows: HeLa (8.130 ± 0.800, *t* = 15.43, *P* = 0.004), ME-180 (4.280 ± 0.400, *t* = 14.9, *P* = 0.005), SiHa (1.760 ± 0.170, *t* = 7.74, *P* = 0.016) and CaSki (6.124 ± 0.534, *t* =16.62, *P* = 0.004). The highest levels of *NEAT1* were observed in CaSki and HeLa cells, while the lowest level of *NEAT1* was detected in SiHa cell. Therefore, these three cells were chosen for next functional assays.

![Upregulated NEAT1 expression in human cervical cancer tissues and cell lines (*n* = 62). (a) qRT-PCR was performed to measure the level of NEAT1 in cervical cancer tissues and corresponding normal tissues. (b) Levels of NEAT1 in different cervical cancer cell lines (HeLa, ME-180, SiHa, and CaSki) and normal human cervical epithelial cell line (H8) were detected by qRT-PCR. \**P* \< 0.05, ^†^*P* \< 0.01 versus control group. NEAT1: Nuclear-enriched abundant transcript 1; qRT-PCR: Quantitative real-time polymerase chain reaction.](CMJ-131-2063-g001){#F1}

Nuclear-enriched abundant transcript 1 correlating with the clinicopathological features and overall survival of cervical cancer patients {#sec2-11}
-----------------------------------------------------------------------------------------------------------------------------------------

We assessed the correlation of *NEAT1* expression with the clinicopathological parameters of 62 patients diagnosed with cervical cancer. The median value of *NEAT1* in all cervical cancer tissues was used as a cutoff value, and all samples were divided into two groups (high expression group: *n* = 29; low expression group: *n* = 33). As presented in [Table 1](#T1){ref-type="table"}, high level of *NEAT1* expression was significantly correlated with larger tumor size (*χ*^2^ = 8.058, *P* = 0.005), poor differentiation (*χ*^2^ = 9.226, *P* = 0.002), International Federation of Gynecology and Obstetrics stage (*χ*^2^ = 4.218, *P* = 0.040), and lymph node metastasis (*χ*^2^ = 5.156, *P* = 0.023) but was no significant correlation with age (*χ*^2^ = 0.827, *P* = 0.363) and histologic type (*χ*^2^ = 2.659, *P* = 0.103). Furthermore, Kaplan-Meier method analysis (log-rank test) was performed to determine the association between *NEAT1* expression and overall survival of patients. As shown in [Figure 2](#F2){ref-type="fig"}, patients with high level of *NEAT1* expression had a significantly shorter overall survival than those with low level of *NEAT1* (*χ*^2^ = 7.735, *P* = 0.005).

###### 

Correlation between lncRNA-*NEAT1* expression and clinical features of patients with cervical cancer (*n* = 62)

  Variables               LncRNA-*NEAT1* expression, *n*   *χ*^2^   *P*     
  ----------------------- -------------------------------- -------- ------- -------
  Age                                                                       
   \<50 years             10                               12       0.827   0.363
   ≥50 years              23                               17               
  Histologic type                                                           
   SCC                    16                               20       2.659   0.103
   AD/ASC                 17                               9                
  FIGO stage                                                                
   Ib--IIa                20                               10       4.218   0.040
   IIb--IIIa              13                               19               
  Large tumor size                                                          
   \<4 cm                 21                               8        8.058   0.005
   ≥4 cm                  12                               21               
  Poor differentiation                                                      
   Well + moderate        27                               13       9.226   0.002
   Poor                   6                                16               
  Lymph node metastasis                                                     
   Negative               27                               16       5.156   0.023
   Positive               6                                13               

NEAT1: Nuclear-enriched abundant transcript 1; SCC: Squamous cell carcinoma; AD: Adenocarcinoma; ASC: Adenosquamous carcinoma. FIGO: International Federation of Gynecology and Obstetrics.

![Correlation between NEAT1 and overall survival of cervical cancer patients was analyzed by Kaplan--Meier method (log-rank test: \**P* = 0.005, *χ*^2^ = 7.735). NEAT1: Nuclear-enriched abundant transcript 1.](CMJ-131-2063-g002){#F2}

Effects of nuclear-enriched abundant transcript 1 knockdown or overexpression on the proliferation and migration of cervical cancer cells {#sec2-12}
-----------------------------------------------------------------------------------------------------------------------------------------

To determine the biological function of *NEAT1* in cervical cancer, gain-of-function or loss-of-function experiments were performed. CaSki and HeLa cells were transfected with si-NEAT1 or si-NC. After 48 h, the transfection efficiency was obtained with qRT-PCR. The expression level of *NEAT1* in cells transfected with si-NC was set as 1, and the expression level of CaSki cell was decreased to 0.174 ± 0.017 (*t* = −83.29, *P* \< 0.001). Moreover, the expression level of HeLa cell was decreased to 0.213 ± 0.021 (*t* = −64.22, *P* \< 0.001). *NEAT1* was overexpressed in SiHa cell through transfecting with pcDNA-NEAT1 (pcDNA3.1 vector containing the whole sequence of NEAT1). The expression level of *NEAT1* in SiHa cell transfected with empty vector (pcDNA-NC) was set as 1, and the expression level of *NEAT1* was increased to 16.820 ± 2.050 (*t* = 13.38, *P* = 0.006) \[[Figure 3a](#F3){ref-type="fig"}\]. Subsequently, functional assays were carried out in these three cells. Cell viability in CaSki cell transfected with si-NEAT1 was decreased from 0.592 ± 0.257 to 0.360 ± 0.091 (*t* = 3.12, *P* = 0.036). Cell viability in HeLa cell transfected with si-NEAT1 was decreased from 0.516 ± 0.208 to 0.328 ± 0.069 (*t* = 2.98, *P* = 0.041). Cell viability of SiHa cell transfected with pcDNA-NEAT1 was increased from 0.314 ± 0.013 to 0.728 ± 0.146 (*t* = 12.16, *P* = 0.017) \[[Figure 3b](#F3){ref-type="fig"}\]. The number of colonies of CaSki cell transfected with si-NEAT1 was decreased from 136.667 ± 13.503 to 71.667 ± 7.506 (*t* = −18.76, *P* = 0.003). The number of colonies of HeLa cell transfected with si-NEAT1 was reduced from 128.667 ± 13.317 to 65.667 ± 7.024 (*t* = −5.54, *P* = 0.031). However, overexpression of *NEAT1* increased the number of colonies in SiHa cell from 84.667 ± 12.014 to 150.667 ± 18.037 (*t* = 7.27, *P* = 0.018) \[[Figure 3c](#F3){ref-type="fig"}\]. Knockdown of *NEAT1* decreased the migratory number of CaSki cell from 100.333 ± 9.866 to 58.333 ± 5.859 (*t* = −8.08, *P* = 0.015) and of HeLa cell from 123.667 ± 12.097 to 67.667 ± 7.095 (*t* = −6.03, *P* = 0.026). Overexpression of *NEAT1* increased the migratory number of SiHa cell from 127.333 ± 16.042 to 231.333 ± 31.786 (*t* = 4.92, *P* = 0.039) \[[Figure 3d](#F3){ref-type="fig"}\].

![Effects of NEAT1 knockdown or overexpression on the proliferation and migration of cervical cancer cells. NEAT1 was silenced in CaSki and HeLa cells through transfecting with si-NEAT1. NEAT1 was overexpressed in SiHa cell through transfecting with pcDNA-NEAT1 (a); the transfection efficiency was measured by qRT-PCR. Effect of NEAT on cell proliferation ability was measured by MTT assay (b) and colony formation assay was stained with 0.1% crystal violet (c). Effect of NEAT knockdown or overexpression on cell migration capacity was measured by Transwell assay. The migratory cells were stained with 0.2% crystal violet (Original magnification ×200; d). \**P* \< 0.05, ^†^*P* \< 0.01, ^‡^*P* \< 0.001 versus control group. NEAT1: Nuclear-enriched abundant transcript 1; qRT-PCR: Quantitative real-time polymerase chain reaction; si-NEAT1: *NEAT1*-specific small-interfering RNA.](CMJ-131-2063-g003){#F3}

Nuclear-enriched abundant transcript 1 activating PI3K/Akt signaling pathway in cervical cancer {#sec2-13}
-----------------------------------------------------------------------------------------------

To determine the possible mechanism by which *NEAT1* regulated the progression of cervical cancer cells, we analyzed the role of PI3K/Akt signal pathway in the function of NEAT1. PI3K/Akt signal pathway had been identified to be aberrantly activated in human cancers and contributed to enhanced cell proliferation and metastasis. Our findings revealed that *NEAT1* positively regulated the levels of p-PI3K and p-Akt in three cervical cancer cells (CaSki, HeLa, and SiHa) \[Figure [4a](#F4){ref-type="fig"}--[4c](#F4){ref-type="fig"}\]. The level of p-PI3K and p-Akt in CaSki or HeLa cells transfected with si-NC was defied as 1. The level of p-PI3K in CaSki cell transfected with si-NEAT1 was decreased to 0.370 ± 0.303 (*t* = −36.03, *P* = 0.001). The level of p-Akt in CaSki cell transfected with si-NEAT1 was decreased to 0.276 ± 0.301 (*t* = −41.67, *P* = 0.010). In HeLa cell transfected with si-NEAT1, the level of p-PI3K was decreased to 0.517 ± 0.515 (*t* = −16.25, *P* = 0.004), and the level of p-Akt was decreased to 0.387 ± 0.038 (*t* = −27.60, *P* = 0.001). SiHa cell was transfected with pcDNA-NEAT1 and pcDNA-NC. The level of p-PI3K and p-Akt in SiHa cell transfected with pcDNA-NC was set as 1. The level of p-PI3K in SiHa cell transfected with pcDNA-NEAT1 was increased to 3.401 ± 0.401 (*t* = 10.38, *P* = 0.009), and the level of p-Akt was increased to 3.106 ± 0.346 (*t* = 10.52, *P* = 0.009).

![PI3K/Akt pathway involved in the function of NEAT1. Western blotting was performed to measure the effects of NEAT1 knockdown or overexpression on the levels of p-PI3K and p-Akt in CaSki cell (a), HeLa cell (b), and SiHa cell (c). \**P* \< 0.05, ^†^*P* \< 0.01 versus control group. N.S: No significance. p: Phosphorylated; NEAT1: Nuclear-enriched abundant transcript 1.](CMJ-131-2063-g004){#F4}

PI3K/Akt pathway involved in the function of nuclear-enriched abundant transcript 1 {#sec2-14}
-----------------------------------------------------------------------------------

To validate whether PI3K/Akt pathway actually involved in the function of *NEAT1* in cervical cancer progression, rescue assays were designed and carried out in different CC cell lines. IGF-1 and LY294002 were known as the activator and inhibitor of PI3K-Akt signaling pathway.\[[@ref16][@ref17]\] IGF-1 and LY294002 were separately utilized in rescue assays. Results of MTT manifested that cell proliferation inhibited by silenced *NEAT1* (*t* = 3.05, *P* = 0.012) as recovered by IGF-1 (*t* = 4.37, *P* = 0.026) \[[Figure 5a](#F5){ref-type="fig"}\]. However, cell proliferation promoted by *NEAT1* overexpression (*t* = 10.33, *P* = 0.030) was attenuated by treating with LY294002 \[[Figure 5a](#F5){ref-type="fig"}\]. Similarly, colony formation assay also revealed that cell proliferation inhibited by silenced *NEAT1* was recovered by IGF-1 (*F* = 9.220, *P* = 0.015). However, cell proliferation promoted by *NEAT1* overexpression was attenuated by treating with LY294002 (*F* = 12.775, *P* = 0.07) \[[Figure 5b](#F5){ref-type="fig"}\]. According to the results of Transwell assay, migration ability inhibited by *NEAT1* knockdown was partly recovered by treating with IGF-1 (*F* = 11.670, *P* = 0.009) \[[Figure 5c](#F5){ref-type="fig"}\]. Conversely, migration ability strengthened by *NEAT1* overexpression was partially weakened when cells were treated with LY294002 (*F* = 14.590, *P* = 0.050). All findings above reflected that *NEAT1* positively regulates cell proliferation and migration in cervical cancer through modulating PI3K/Akt signaling pathway.

![PI3K/Akt pathway involved in the function of NEAT1. Effects of IGF-1 or LY294002 on si-NEAT1/pcDNA-NEAT1-mediated cell proliferation were evaluated using MTT assay (a) and colony formation assay (b). Effects of IGF-1 on si-NEAT1-mediated cell migration were measured. The effects of LY294002 on pcDNA-NEAT1-mediated cell migration were examined with Transwell assay (c). \**P* \< 0.05, ^†^*P* \< 0.01 versus control group. NEAT1: Nuclear-enriched abundant transcript 1; si-NEAT1: *NEAT1*-specific small-interfering RNA.](CMJ-131-2063-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Previous reports have revealed that dysregulation of *NEAT1* greatly affects the prognosis of cancer patients.\[[@ref18][@ref19]\] This study revealed the prognostic implication of *NEAT1* in cervical cancer. The high expression of *NEAT1* predicted poor prognosis for cervical cancer patients. Although the clinical samples used in this study are limited, our research results still make senses. These results suggested that *NEAT1* had the oncogenic property in cervical cancer. The specific biological function of *NEAT1* is worth further investigating.

Many studies have revealed the oncogenic property of *NEAT1* in human cancers.\[[@ref20][@ref21][@ref22]\] The biological function of *NEAT1* was demonstrated in the above malignant tumors by loss-of-function assays. In this study, we applied both loss-of-function and gain-of-function assays to prove the effects of *NEAT1* on cellular processed in cervical cancer. Silenced *NEAT1* is able to inhibited proliferation and migration of cervical cancer cells, while overexpression of *NEAT1* suppressed cell proliferation and migration of cervical cancer cell. *NEAT1* positively modulated cell proliferation and migration in cervical cancer. These results suggested that *NEAT1* exerts as an oncogene in cervical cancer progression by promoting cell proliferation and migration. Based on the experimental results, the oncogenic role of *NEAT1* was identified in cervical cancer. Although this study only studied the effects of *NEAT1* on cell proliferation and migration, the experimental results still help identify the oncogenic property of *NEAT1* in cervical cancer.

A lot of previous studies have demonstrated that PI3K/Akt signaling pathway involved in the lncRNAs-mediated function in many biological processes.\[[@ref23][@ref24]\] This study was focus on whether PI3K/Akt signaling pathway involved in NEAT1-mediated cell proliferation and migration in cervical cancer. We found that *NEAT1* promoted the level of p-PI3K and p-Akt. The result indicated that *NEAT1* positively affected the activation of PI3K/Akt signaling pathway. Using the activator (IGF-1) and inhibitor (LY294002) of PI3K-Akt signaling pathway, we identified that the effects of *NEAT1* on cell proliferation and migration were mediated by the PI3K-Akt signaling. Taken together, we confirmed that promoted cell proliferation and migration in cervical cancer by activating PI3K/Akt signaling pathway. Therefore, *NEAT1* may be considered as potential therapy target for cervical cancer. Since this study did not deeply explore the molecular mechanism by which *NEAT1* regulated cervical cancer progression, we will make further investigation in the future.
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